WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H522464
CAS#: 1402002-76-9
Description: PF-06442609 is a potent, metabolic stable γ-secretase modulators (GSMs) for Alzheimer's disease (AD). PF-06442609 displayed a favorable rodent pharmacokinetic profile, and robust reductions of brain Aβ42 and Aβ40 were observed in a guinea pig time-course experiment. F-06442609 is suitable for rodent model of AD.
Hodoodo Cat#: H522464
Name: PF-06442609
CAS#: 1402002-76-9
Chemical Formula: C24H24F4N4O3
Exact Mass: 492.18
Molecular Weight: 492.475
Elemental Analysis: C, 58.53; H, 4.91; F, 15.43; N, 11.38; O, 9.75
Synonym: PF-06442609; PF 06442609; PF06442609; PF-6442609; PF 6442609; PF6442609.
IUPAC/Chemical Name: 2-((S)-1-(4-fluoro-2-((R)-1,1,1-trifluoropropan-2-yl)phenoxy)propan-2-yl)-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione
InChi Key: XZFBQMFLEPCQCW-JKSUJKDBSA-N
InChi Code: InChI=1S/C24H24F4N4O3/c1-14-11-30(13-29-14)19-5-6-20-23(34)31(8-9-32(20)22(19)33)15(2)12-35-21-7-4-17(25)10-18(21)16(3)24(26,27)28/h4-7,10-11,13,15-16H,8-9,12H2,1-3H3/t15-,16+/m0/s1
SMILES Code: O=C1C(N2CCN1[C@@H](C)COC3=CC=C(F)C=C3[C@@H](C)C(F)(F)F)=CC=C(N4C=C(C)N=C4)C2=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 492.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Pettersson M, Johnson DS, Humphrey JM, Butler TW, Am Ende CW, Fish BA, Green
ME, Kauffman GW, Mullins PB, O'Donnell CJ, Stepan AF, Stiff CM, Subramanyam C,
Tran TP, Vetelino BC, Yang E, Xie L, Bales KR, Pustilnik LR, Steyn SJ, Wood KM,
Verhoest PR. Design of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align
Potency, MDR Efflux Ratio, and Metabolic Stability. ACS Med Chem Lett. 2015 Apr
3;6(5):596-601. doi: 10.1021/acsmedchemlett.5b00070. eCollection 2015 May 14.
PubMed PMID: 26005540; PubMed Central PMCID: PMC4434474.